

# Global Summit on PANCREAS, GASTROENTEROLOGY AND DIGESTIVE DISEASES

September 09, 2022 | Webinar

## Role of peptide receptor polynucleide therapy in the management of pancreatic neuroendocrine tumors

**Neha Sharma**

*Lady Hardinge Medical College, India*

7% of all pancreatic neoplasms are pancreatic neuroendocrine tumours, a subset of endocrine tumours. They come in two flavours: benign and malignant. They can present as either slowly expanding, non-infiltrative, benign masses or rapidly spreading, highly aggressive, metastasizing tumours. There was a lack of scientific information on the diagnosis and approach to treating these neoplasms in the past, but in recent years, ongoing research has implied a wealth of information about the classification, prognostic stratification, and treatment of pancreatic neuroendocrine tumours. We will talk about the epidemiology, clinical appearance, classification, diagnosis, and treatment of these cancers in this section. We will also discuss the most recent advancements in the care of pancreatic neuroendocrine tumours, with a particular emphasis on the function of peptide receptor radionuclide therapy (PRRT). PRRT with radiolabeled somatostatin analogs is an innovative treatment for inoperable or metastasized, well/moderately differentiated, Neuroendocrine tumors.

### Biography

Neha Sharma has completed her post graduation in oncology from S.N.Medical College Agra and her senior residency from Maulana Azad Medical College New Delhi. She has received P.G. appreciation award by National Medicos Organisation, India. She is currently working as assistant professor in the department of radiation oncology, Lady Hardinge Medical College, New Delhi. She has published multiple papers and chapters in reputed national and international journals and has been serving as an editorial board member of reputed.